Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
Rhea-AI Summary
Editas Medicine (Nasdaq: EDIT) updated the timing of its appearance at the 2026 Jefferies Global Healthcare Conference. The company will now present on June 4, 2026 at 2:00 p.m. ET in New York, with a live webcast and 30-day replay via its investor website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – EDIT
On the day this news was published, EDIT gained 0.87%, reflecting a mild positive market reaction. Argus tracked a trough of -12.1% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $503.35M at that time.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will now present at the 2026 Jefferies Global Healthcare Conference at 2:00 p.m. ET on Thursday, June 4, 2026.
Updated Conference Details:
- 2026 Jefferies Global Healthcare Conference
Format: Presentation
Date: June 4, 2026
Time: 2:00 p.m. ET
New York, NY
To access the live webcast of Editas Medicine’s presentation, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the event.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Investor and Media Contacts: ir@editasmed.com media@editasmed.com